Compare
ENDRA Life Sciences Inc. vs Nexalin Technology, Inc. vs Escalon Medical Corp vs Nuwellis, Inc.
| Latest fiscal year | ENDRA Life Sciences Inc. NDRA | Nexalin Technology, Inc. NXL | Escalon Medical Corp ESMC | Nuwellis, Inc. NUWE |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-06-30 | 2025-12-31 |
| Revenue | n/a | $301.6K | $12.05M | $8.27M |
| Revenue growth (YoY) | n/a | +78.8% | +0.5% | -5.4% |
| Gross margin | n/a | 79.7% | 45.7% (computed) | 62.0% |
| Operating margin | n/a | n/m | 1.1% | -134.3% |
| Net margin | n/a | n/m | 0.9% | -211.9% |
| Net income | -$7.03M | -$8.22M | $105.5K | -$17.52M |
| EPS (Diluted) | -$8.93 | -$0.50 | $0.00 | -$25.39 |
| Operating cash flow | -$5.18M | -$4.96M | $380.7K | -$10.81M |
| Free cash flow | -$5.20M | n/a | $376.8K | -$10.90M |
| Cash & equivalents | n/a | $654.8K | $545.8K | $1.08M |
| Total assets | $3.85M | $4.64M | $4.99M | $6.12M |
| Total liabilities | $1.59M | $887.3K | $3.08M | $3.49M |
| Shareholders' equity | $2.26M | $3.75M | $1.92M | $2.62M |
| Return on year-end equity | -310.9% | -219.4% | 5.5% | -667.7% |
| Shares outstanding | 1.18M | 19.19M | 7.42M | 1.69M |
Revenue, most recent five fiscal years
| Fiscal year | ENDRA Life Sciences Inc. | Nexalin Technology, Inc. | Escalon Medical Corp | Nuwellis, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2020-12-31 | $301.6K Ended 2025-12-31 | $12.05M Ended 2025-06-30 | $8.27M Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2019-12-31 | $168.7K Ended 2024-12-31 | $11.98M Ended 2024-06-30 | $8.74M Ended 2024-12-31 |
| 2 years earlier | $6.2K Ended 2018-12-31 | $110.7K Ended 2023-12-31 | $12.18M Ended 2023-06-30 | $8.86M Ended 2023-12-31 |
| 3 years earlier | $351.6K Ended 2017-12-31 | $1.32M Ended 2022-12-31 | $10.70M Ended 2022-06-30 | $8.54M Ended 2022-12-31 |
| 4 years earlier | $515.6K Ended 2016-12-31 | $144.1K Ended 2021-12-31 | $10.47M Ended 2021-06-30 | $7.92M Ended 2021-12-31 |